CD38 and prostate carcinoma: Overexpression of CD38 in prostate cancer cells leads to an increase in pAMPK levels, a decrease in fatty acid and lipid synthesis, reduced glycolysis and metabolism, and an extended cell doubling time, ultimately resulting in a decrease in tumor cell proliferation [50].